Document Detail


Immunomodulation in the treatment of multiple sclerosis and amyotrophic lateral sclerosis: a model for autoimmune disorders.
MedLine Citation:
PMID:  7674346     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Seventeen multiple sclerosis (MS) patients progressing under conventional therapy (average treatment duration: 3 years) with performance status 3-4 (mean Disability Status Scale [DSS]: 82) who demonstrated circulating lymphokine inhibitor factors were selected for a monthly immunomodulatory protocol using plasmapheresis, followed by 3 days of human intravenous immunoglobulin, and low-dose methylprednisolone, cyclophosphamide, interferon-a, and interferon-g, as well as octreide. Twelve of the 17 patients presented with visual problems, 12 had lower extremity weakness or paraperesis/paralysis, and 6 had bladder/bowel dysfunction. Following 4 months of therapy, 4 recovered completely, 7 showed loss of paralysis/paraparesis, and 5 had improvement in lower extremity weakness. One patient progressed (mean DSS: 51). Lymphokine inhibitor factors declined in 14 patients with concomitant normalization of circulating immune complexes. Eight patients experienced rises in CD4 levels with stabilization of CD8 levels. Hypotension and hypocalcemia were observed during plasmapheresis. Twelve patients with amyotrophic lateral sclerosis with poor performance status also were studied. Four of the 12 improved with the regimen, whereas six stabilized disease. Similar alterations in laboratory parameters were described. The rationale for this approach is discussed.
Authors:
K Alonso; R Medenica
Related Documents :
16987836 - Vasoactive therapies in systemic sclerosis.
18676406 - Serum homocysteine levels in relation to clinical progression in multiple sclerosis.
1506866 - Mri findings of multiple sclerosis with acute transverse myelopathy.
18424476 - Clinical features of patients with multiple sclerosis from a survey in shanghai, china.
15624436 - Severe lymphatic microangiopathy in fabry disease.
11606666 - A clinical role for [(123)i]mibg myocardial scintigraphy in the distinction between dem...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of the National Medical Association     Volume:  87     ISSN:  0027-9684     ISO Abbreviation:  J Natl Med Assoc     Publication Date:  1995 Aug 
Date Detail:
Created Date:  1995-10-17     Completed Date:  1995-10-17     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  7503090     Medline TA:  J Natl Med Assoc     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  561-8     Citation Subset:  IM    
Affiliation:
Institute for Advanced Studies in Medicine, Atlanta, Georgia, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adjuvants, Immunologic / therapeutic use*
Adult
Aged
Amyotrophic Lateral Sclerosis / complications,  therapy*
Autoimmune Diseases / complications,  therapy*
Female
Humans
Male
Middle Aged
Multiple Sclerosis / complications,  therapy*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Adjuvants, Immunologic
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ki-67 reactivity in breast carcinoma analyzed by a computer-assisted image system: preliminary resul...
Next Document:  Adrenal hemorrhage: a comparison of traumatic and nontraumatic deaths.